New drug combo aims to extend life in tough lung cancer
NCT ID NCT05874401
First seen Nov 01, 2025 · Last updated May 26, 2026 · Updated 33 times
Summary
This study tests if a drug called trilaciclib, given before chemotherapy, helps people with advanced small cell lung cancer live longer. About 302 participants will receive either trilaciclib or a placebo alongside their chemo. The goal is to see if the drug improves survival without making side effects worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital
RECRUITINGSeville, Spain
Contact
Conditions
Explore the condition pages connected to this study.